Silgan (SLGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting scheduled for May 26, 2026, to elect three directors, approve an amendment to the stock incentive plan, ratify the external auditor, and hold a say-on-pay advisory vote.
Record date for voting is April 2, 2026, with 105,679,758 shares of common stock outstanding, each entitled to one vote.
Proxy materials and annual report are available online for shareholder review.
Voting matters and shareholder proposals
Election of three Class II directors to serve until 2029.
Approval sought for the First Amendment to the Second Amended and Restated 2004 Stock Incentive Plan, increasing shares available and extending plan term.
Ratification of Ernst & Young LLP as independent auditor for fiscal 2026.
Advisory vote on executive compensation (say-on-pay) included.
Board of directors and corporate governance
Board consists of nine members in staggered three-year terms across three classes.
Six directors are independent per NYSE standards; independent directors meet regularly without management.
Board committees: Audit, Compensation, and Nominating, all comprised of independent directors.
Board leadership is separated between Chairperson and CEO roles.
Stockholders Agreement allows founders' group to nominate one director if they own at least 5% of shares.
Latest events from Silgan
- Record 2025 growth in key segments, with further earnings and cash flow gains expected in 2026.SLGN
Q4 20254 Feb 2026 - €838M acquisition expands dispensing leadership, targets €20M synergies and 10% EPS accretion.SLGN
M&A Announcement3 Feb 2026 - Q2 net sales fell 3.2% to $1.38B, but gross margin and adjusted EPS both increased.SLGN
Q2 20242 Feb 2026 - Q3 2024 saw record dispensing growth and Weener acquisition, setting up strong 2025 prospects.SLGN
Q3 202417 Jan 2026 - Record Q4 results and 2025 double-digit growth outlook driven by acquisitions and dispensing demand.SLGN
Q4 20249 Jan 2026 - Record Q1 2025 sales and earnings growth driven by Weener acquisition and volume gains.SLGN
Q1 202524 Dec 2025 - Proxy covers director elections, auditor ratification, say-on-pay, and strong governance.SLGN
Proxy Filing1 Dec 2025 - Record Q2 sales, 15% EPS growth, and strong outlook despite $20M EBIT headwinds.SLGN
Q2 202516 Nov 2025 - Q3 sales up 15.1% to $2.01B, with strong pet food and fragrance, but Q4 faces volume headwinds.SLGN
Q3 20255 Nov 2025